| Evaluation of drug penetration into the brain: a double study by in vivo imaging with positron emission tomography and using an in vitro model of the human blood-brain barrier. | |
| | |
MedLine Citation:
|
PMID: 16210395 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The blood-brain barrier (BBB) permeabilities of 11 compounds were measured both in vitro with a newly developed coculture-based model of human BBB and in vivo with positron emission tomography (PET). The 11 compounds were fluoropyridinyl derivatives labeled with the positron-emitter fluorine-18, [(18)F]F-A-85380 [2-[(18)F]fluoro-3-[2(S)-2 azetidinylmethoxy]pyridine], and 10 selected N-substituted-azetidinyl and pyrrolidinyl closely related [(18)F]fluoropyridinyl derivatives (including [N'-aromatic/aliphatic]-thioureas, -ureas, and -amides). The in vitro BBB model, a new coculture system of primary human brain endothelial cells and astrocytes, was used to measure the permeability coefficient for each compound. Dynamic PET studies were performed in rats with the same compounds, and a two-compartment model analysis was used to calculate their in vivo permeability coefficients. The 11 derivatives differed in their degree of BBB passage and transport mechanism. The analysis of PET data showed a significant cerebral uptake for six derivatives, for which the in vitro evaluation indicated active influx or free diffusion. Five derivatives displayed low in vivo cerebral uptake, in agreement with the observation of an in vitro active efflux. Overall, there was a remarkable correlation between the in vitro and in vivo permeability coefficients (r = 0.99). This double study proves a close correlationship between the assessment of the BBB passage in vitro and in vivo. The in vitro model of human BBB offers the possibility of subtle discrimination of various BBB permeability degrees and transport mechanisms. Conversely, small animal PET imaging appears suitable to screen directly in vivo brain targeting of drugs or radiopharmaceutical candidates. |
| | |
Authors:
|
Véronique Josserand; Hélène Pélerin; Béatrice de Bruin; Benoît Jego; Bertrand Kuhnast; Françoise Hinnen; Frédéric Ducongé; Raphaël Boisgard; Frédéric Beuvon; Francine Chassoux; Catherine Daumas-Duport; Eric Ezan; Frédéric Dollé; Aloïse Mabondzo; Bertrand Tavitian |
Related Documents
:
|
20963845 - Application of the aqueous porous pathway model to quantify the effect of sodium lauryl... 15720765 - Skin color correction for tissue spectroscopy: demonstration of a novel approach with t... 10390015 - A new method for continuous tonometric pco2 measurement--in vitro studies. 21341745 - A novel approach for predicting p-glycoprotein (abcb1) inhibition using molecular inter... 21958005 - Multilocus association mapping using generalized ridge logistic regression. 3503855 - Prediction of the range of hand positions available to a patient with movement restrict... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2005-10-06 |
Journal Detail:
|
Title: The Journal of pharmacology and experimental therapeutics Volume: 316 ISSN: 0022-3565 ISO Abbreviation: J. Pharmacol. Exp. Ther. Publication Date: 2006 Jan |
Date Detail:
|
Created Date: 2005-12-22 Completed Date: 2006-03-31 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 0376362 Medline TA: J Pharmacol Exp Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 79-86 Citation Subset: IM |
Affiliation:
|
Commissariat à l'Energie Atomique, Service Hospitalier Frédéric Joliot, Orsay, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Algorithms Animals Astrocytes / drug effects, metabolism Azetidines / diagnostic use Biological Transport, Active / drug effects Blood-Brain Barrier / physiology* Brain / metabolism*, radionuclide imaging* Buffers Chemistry, Physical Coculture Techniques Humans Microscopy, Fluorescence Models, Biological Molecular Weight Pharmaceutical Preparations / metabolism* Physicochemical Phenomena Positron-Emission Tomography Pyridines / diagnostic use Radiopharmaceuticals / diagnostic use, pharmacokinetics Rats Receptors, Nicotinic / drug effects, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/2-fluoro-3-(2-azetidinylmethoxy)pyridine; 0/Azetidines; 0/Buffers; 0/Pharmaceutical Preparations; 0/Pyridines; 0/Radiopharmaceuticals; 0/Receptors, Nicotinic; 0/nicotinic receptor alpha4beta2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antimelanoma activity of apoptogenic carbonyl scavengers.
Next Document: Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disea...